Lawrence D. Mayer

10.4k citations

140 papers · 8.7k indexed · 1 hit paper · h-index 52

Impact in

Biomaterials top 0.1%
- Nanoparticle-Based Drug Delivery
Pharmaceutical Science top 0.5%

Papers in

Biomaterials 69
- Nanoparticle-Based Drug Delivery 69
Hematology 18
- Acute Myeloid Leukemia Research 16

Co-authors: Marcel B. Bally Rajesh Krishna Pieter R. Cullis Paul Tardi Troy O. Harasym Jennifer A. Shabbits Sharon A. Johnstone Michael J. Hope
Journals: Biochimica et Biophysica Acta (BBA) - Biomembranes (22 papers)Cancer Research (10 papers)Cancer Chemotherapy and Pharmacology (7 papers)Journal of Liposome Research (7 papers)Blood (7 papers)
Partner nations: Canada United States Sweden

In The Last Decade

Lawrence D. Mayer

139 papers receiving 8.3k citations

Hit Papers

align trajectories log scale

Multidrug resistance (MDR) in cancer 2000 · 883 citations

Peers

Countries citing papers authored by Lawrence D. Mayer

Since Specialization

Citations

This map shows the geographic impact of Lawrence D. Mayer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence D. Mayer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence D. Mayer more than expected).

Fields of papers citing papers by Lawrence D. Mayer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence D. Mayer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence D. Mayer. The network helps show where Lawrence D. Mayer may publish in the future.

Co-authors

The 25 scholars most cited alongside Lawrence D. Mayer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lawrence D. Mayer Line = papers co-authored together Lawrence D. Mayer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML Leukemia Research ·Elizabeth Anderson, Priyanka Mehta, Jonathan Heywood, Erwan Le Nezet, Heather K. Bone, Gareth Robinson, Darren M. Reynolds, Vyv Salisbury, Lawrence D. Mayer	2018	3
2	Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion Journal of Controlled Release ·Stęphan T. Stern, Peng Zou, Amany Atf Elkarim Abou Zaid, Sherwin Xie, Barry D. Liboiron, Troy O. Harasym, Paul Tardi, Lawrence D. Mayer, Scott E. McNeil	2013	8
3	Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells Experimental Hematology ·Hyun Pyo Kim, Brigitte Gerhard, Troy O. Harasym, Lawrence D. Mayer, Donna E. Hogge	2011	64
4	Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts Leukemia Research ·Wah-Seng Lim, Paul Tardi, Nancy Dos Santos, Xiaowei Xie, Mannie Fan, Barry D. Liboiron, 宗合, Troy O. Harasym, David Bermudes, Lawrence D. Mayer	2010	118
5	Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors Clinical Cancer Research ·Gerald Batist, Karen A. Gelmon, Kim N., Wilson H. Miller, Stephen Chia, Lawrence D. Mayer, Christine E. Swenson, Andrew S. Janoff, Arthur C. Louie	2009	166
6	Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo Molecular Cancer Therapeutics ·Paul Tardi, Nancy Dos Santos, Troy O. Harasym, Sharon A. Johnstone, Natalia Zisman, Sergio A. Alvarez Cardenas, David Bermudes, Lawrence D. Mayer	2009	98
7	Development of highly efficacious hydrophobic paclitaxel prodrugs delivered in nanoparticles for fixed-ratio drug combination applications Cancer Research ·Steven M. Ansell, Sharon A. Johnstone, Paul Tardi, Zhao Changgeng, Sherwin Xie, Yu Shu, Troy O. Harasym, Natashia Harasym, Laura Williams, David Bermudes, Barry D. Liboiron, Walid Saad, Robert K. Prud’homme, Lawrence D. Mayer	2008	3
8	Synergistic antitumor activity observed for a fixed ratio liposome formulation of Cytarabine (Cyt):Daunorubicin (Daun) against preclinical leukemia models Cancer Research ·Sharon A. Johnstone, Pierrot Harvie, Madaeni Seyed Siavosh, Salam Kadhim, Troy O. Harasym, Paul Tardi, Natashia Harasym, Marcel B. Bally, Lawrence D. Mayer	2005	3
9	A pharmaceutical approach to achieve synergy in vivo: A fixed ratio formulation of Irinotecan and Floxuridine for treatment of colorectal cancer Cancer Research ·Lawrence D. Mayer, Troy O. Harasym, Natashia Harasym, Paul Tardi, Yu Shu, 麻穂岸本, María C. Espíndola, Marcel B. Bally	2004	2
10	A novel approach to prepare a liposomal irinotecan formulations that exhibit significant therapeutic activity in vivo Cancer Research ·Euan Ramsay, Oladunni M Ayodele, Malathi Anantha, Awa Dicko, Pierrot Harvie, Lawrence D. Mayer, Marcel B. Bally, Paul Tardi	2004	1
11	pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol Biochimica et Biophysica Acta (BBA) - Biomembranes ·Nancy Dos Santos, Chunzhi Cao, J. Dérerová, Mansyur Akil, Ryan Gallagher, Göran Karlsson, Katarina Edwards, Lawrence D. Mayer, Christine Allen, Marcel B. Bally	2003	86
12	Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis Biochimica et Biophysica Acta (BBA) - Biomembranes ·Gigi Ngar Chee Chiu, Marcel B. Bally, Lawrence D. Mayer	2003	26
13	Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro Biochimica et Biophysica Acta (BBA) - Biomembranes ·Jennifer A. Shabbits, Lawrence D. Mayer	2003	80
14	Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P‐glycoprotein PubMed ·Lawrence D. Mayer, Kye‐Taek Lim, Necati Bulut	2002	4
15	The Role for Liposomal Drug Delivery in Molecular and Pharmacological Strategies to Overcome Multidrug Resistance Cancer and Metastasis Reviews ·Lawrence D. Mayer, Jennifer A. Shabbits	2001	34
16	Drug-Drug Interactions Arising From the Use of Liposomal Vincristine in Combination with Other Anticancer Drugs Pharmaceutical Research ·Dawn Waterhouse, Nancy Dos Santos, Lawrence D. Mayer, Marcel B. Bally	2001	4
17	Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression Breast Cancer Research and Treatment ·Kim N., Wen Ma, Véronique Dagues, Achmad Albunsyary, Deborah J. Stenzel, Wieslawa H. Dragowska, Lawrence D. Mayer	2000	58
18	Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine Biochimica et Biophysica Acta (BBA) - Biomembranes ·Murray S. Webb, E M Stamm, Frances M. P. Wong, Howard J. Lim, Zhao Wang, Marcel B. Bally, Lewis S. L. Choi, Pieter R. Cullis, Lawrence D. Mayer	1998	146
19	Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer Cancer Chemotherapy and Pharmacology ·Murray S. Webb, Z. ZEMAN, Peter M. Kanter, Grzegorz Trafalski, Karen A. Gelmon, Troy O. Harasym, Lawrence D. Mayer, Marcel B. Bally	1998	54
20	Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice Cancer Chemotherapy and Pharmacology ·Marcel B. Bally, Dana Masin, Rajiv Nayar, Pieter R. Cullis, Lawrence D. Mayer	1994	52

About Lawrence D. Mayer

Lawrence D. Mayer is a scholar working on Biomaterials, Hematology, Oncology, Molecular Biology and Pharmaceutical Science, having authored 140 papers that have together received 8.7k indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (69 papers), Lipid Membrane Structure and Behavior (32 papers), RNA Interference and Gene Delivery (28 papers), Advanced biosensing and bioanalysis techniques (21 papers), Cancer therapeutics and mechanisms (18 papers), Drug Transport and Resistance Mechanisms (17 papers), Acute Myeloid Leukemia Research (16 papers) and Cancer Treatment and Pharmacology (14 papers). The work is most often cited by research in Biomaterials (3.8k citations), Pharmaceutical Science (695 citations), Oncology (2.1k citations), Molecular Biology (5.0k citations) and Hematology (782 citations). Lawrence D. Mayer has collaborated with scholars based in Canada, United States and Sweden. Frequent co-authors include Marcel B. Bally, Rajesh Krishna, Pieter R. Cullis, Paul Tardi, Troy O. Harasym, Jennifer A. Shabbits, Sharon A. Johnstone, Michael J. Hope, Dana Masin and Dawn Waterhouse. Their work appears in journals such as Biochimica et Biophysica Acta (BBA) - Biomembranes, Cancer Research, Cancer Chemotherapy and Pharmacology, Journal of Liposome Research and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact